Matsumura Yugo, Ichihara Seiya, Nii Kaori, Nanjo Kazumasa, Kadota Naoki, Okano Yoshio, Machida Hisanori, Hatakeyama Nobuo, Hino Hiroyuki, Naruse Keishi, Shinohara Tsutomu, Sakiyama Shoji, Tacheuchi Eiji
Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Department of Thoracic Surgery, National Hospital Organization Kochi Hospital, Kochi, Japan.
Cancer Rep (Hoboken). 2025 Jul;8(7):e70273. doi: 10.1002/cnr2.70273.
Epidermal growth factor receptor (EGFR) mutations in squamous cell lung carcinoma are rare. EGFR-tyrosine kinase inhibitors are generally less effective for EGFR-mutated squamous cell lung carcinoma. We herein present a case of EGFR-mutated squamous cell lung carcinoma that responded to osimertinib.
A 75-year-old woman with bloody sputum and left back pain was referred to NHO Kochi Hospital. A mass was observed in the left lower lobe on chest CT. Squamous cell lung carcinoma, cT4N1M1b (adrenal metastasis) stage IVA, was diagnosed based on the findings of a CT-guided percutaneous lung biopsy and a CT scan revealing right adrenal metastasis. The primary tumor was subjected to a genomic analysis with the AmoyDx Pan Lung Cancer PCR panel, which revealed an EGFR mutation (exon 21 L858R). The PD-L1 tumor proportion score was 95%. Osimertinib was initiated as first-line targeted therapy. Tumor shrinkage was observed and maintained over 9 months of treatment.
We encountered a rare EGFR-mutated squamous cell lung carcinoma that responded well to osimertinib. Osimertinib may be an option for the treatment of patients with EGFR-mutated squamous cell lung carcinoma.
肺鳞状细胞癌中表皮生长因子受体（EGFR）突变罕见。EGFR酪氨酸激酶抑制剂对EGFR突变的肺鳞状细胞癌通常疗效较差。我们在此报告1例对奥希替尼有反应的EGFR突变肺鳞状细胞癌病例。
一名75岁女性，有咯血和左背痛，转诊至高知市立医院。胸部CT显示左下叶有一肿块。根据CT引导下经皮肺穿刺活检结果及CT扫描显示右肾上腺转移，诊断为肺鳞状细胞癌，cT4N1M1b（肾上腺转移）IVA期。对原发性肿瘤采用厦门艾德泛肺癌PCR检测试剂盒进行基因分析，结果显示存在EGFR突变（外显子21 L858R）。PD-L1肿瘤比例分数为95%。开始使用奥希替尼作为一线靶向治疗。治疗9个月期间观察到肿瘤缩小且持续存在。
我们遇到1例罕见的EGFR突变肺鳞状细胞癌，对奥希替尼反应良好。奥希替尼可能是治疗EGFR突变肺鳞状细胞癌患者的一种选择。
